Praxis Precision Medicines Announces Positive, Best-in-Disease Topline Results in Patients With Focal Onset Seizures From the RADIANT Study of Vormatrigin
A phase 2 trial evaluated vormatrigine, a once-daily selective sodium channel blocker, for seizure reduction and safety in patients with focal onset...